Cost-effectiveness is a new and rapidly expanding field of modern medicine. As new therapies continue to be introduced in the market, some of them being quite expensive, the cost related to healthcare in different clinical settings is constantly increasing. Therefore, a modern approach in healthcare politics is based on the calculation of cost-effectiveness, which reflects the balance between the cost of a therapy and its efficiency, translated into years of survival or quality of life. Heart failure (HF) is a disease which consumes a significant part of healthcare budget, most of its expenditures being represented by hospitalization costs. Several published studies reported that approximately two-thirds of the healthcare costs of HF are related to hospitalization. 1,2 A current cost-of-illness systematic review highlights the latest worldwide estimations, suggesting that approximately 26 million individuals are affected by HF, 3 with an expected prevalence of at least 3% by 2030, leading some to describe it as a global pandemic. 4 Annually, both Europe and the US spend 1-2% of their healthcare resources for the management of HF. 5 In terms of global economic burden, the healthcare of patients with HF has been assessed at $108 billion each year, with $65 billion credited to direct and $43 billion to indirect costs. The United States represents the largest contributor to worldwide HF charges and is responsible for 28.4% of overall HF costs, while Europe accounts for 6.83% of overall HF expenditure. 6 Patients with chronic HF require frequent rehospitalizations, which significantly increases the economic burden of this devastating disease. A recently published review confirms that hospital admission-related costs contribute significantly to global HF-related direct costs, in a percentage between 44% and 96%. 3 These readmissions proved to be specifically resource-intensive, as healthcare costs were estimated to $83,980 over the lifetime of each patient with HF. Another study reported that from global lifetime healthcare costs related to HF, almost 80% were associated with hospital stays. 7 Chronic HF is a condition in which the heart cannot pump sufficient blood into the circulation to satisfy the needs of the entire body. The latest statistical report of the American Heart Association estimates that 0.4-2.2% of the population in industrialized states present this condition, with between 500,000-600,000 incident cases diagnosed per year. 8 As a chronic disease, HF involves great lifetime expenses, mainly in the first year after diagnosis, while end-of-life healthcare is defined as the most expensive one. 2
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Anemia is a frequent comorbidity in patients with
The mechanisms by which different therapies may improve the evolution of chronic diseases can be very complex. For instance, it has been reported that the administration of ACE inhibitors associated with nonsteroidal anti-inflammatory drugs significantly improves the process of chronic inflammation in several groups of patients. 16 However, their administration in acute phases of cardiac diseases may lead to a clinical benefit which is independent on the long-term administration. Similarly, iron administration in chronic HF may improve the longterm prognosis of these patients, but iron infusion during acute episodes of HF decompensation, when associated to proper therapies for acute HF, can play a definite contribution to the immediate restoration of hemodynamic status via different mechanisms of action.
All these indicate that modern therapies that proved to be cost-effective should be evaluated not only in chronic conditions but also in acute clinical settings, in order to validate the therapy on a larger scale.
